Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis

Thomas H. Sisson, Iyabode O. Ajayi, Natalya Subbotina, Amos Dodi, Eva S. Rodansky, Lauren N. Chibucos, Kevin K. Kim, Venkateshwar G. Keshamouni, Eric S. White, Yong Zhou, Peter D R Higgins, Scott D. Larsen, Richard R. Neubig, Jeffrey C. Horowitz

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Myofibroblasts are crucial to the pathogenesis of tissue fibrosis. Their formation of stress fibers results in the release of myocardin-related transcription factor (MRTF), a transcriptional coactivator of serum response factor (SRF). MRTF-A (Mkl1)-deficient mice are protected from lung fibrosis. We hypothesized that the SRF/MRTF pathway inhibitor CCG-203971 would modulate myofibroblast function in vitro and limit lung fibrosis in vivo. Normal and idiopathic pulmonary fibrosis lung fibroblasts were treated with/without CCG-203971 (N-[4-chlorophenyl]-1-[3-(2-furanyl)benzoyl]-3-piperidine carboxamide) and/or Fas-activating antibody in the presence/absence of transforming growth factor (TGF)-β1, and apoptosis was assessed. In vivo studies examined the effect of therapeutically administered CCG-203971 on lung fibrosis in two distinct murine models of fibrosis induced by bleomycin or targeted type II alveolar epithelial injury. In vitro, CCG-203971 prevented nuclear localization of MRTF-A; increased the apoptotic susceptibility of normal and idiopathic pulmonary fibrosis fibroblasts; blocked TGF-β1-induced myofibroblast differentiation; and inhibited TGF-β1-induced expression of fibronectin, X-linked inhibitor of apoptosis, and plasminogen activator inhibitor-1. TGF-β1 did not protect fibroblasts or myofibroblasts from apoptosis in the presence of CCG-203971. In vivo, CCG-203971 significantly reduced lung collagen content in both murine models while decreasing alveolar plasminogen activator inhibitor-1 and promoting myofibroblast apoptosis. These data support a central role of the SRF/MRTF pathway in the pathobiology of lung fibrosis and suggest that its inhibition can help resolve lung fibrosis by promoting fibroblast apoptosis.

Original languageEnglish (US)
Pages (from-to)969-986
Number of pages18
JournalAmerican Journal of Pathology
Volume185
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Serum Response Factor
Myofibroblasts
Fibrosis
Transcription Factors
Apoptosis
Lung
Transforming Growth Factors
Fibroblasts
Idiopathic Pulmonary Fibrosis
Plasminogen Activator Inhibitor 1
Stress Fibers
Bleomycin
myocardin
Fibronectins
N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide
Collagen
Antibodies
Wounds and Injuries

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis. / Sisson, Thomas H.; Ajayi, Iyabode O.; Subbotina, Natalya; Dodi, Amos; Rodansky, Eva S.; Chibucos, Lauren N.; Kim, Kevin K.; Keshamouni, Venkateshwar G.; White, Eric S.; Zhou, Yong; Higgins, Peter D R; Larsen, Scott D.; Neubig, Richard R.; Horowitz, Jeffrey C.

In: American Journal of Pathology, Vol. 185, No. 4, 01.04.2015, p. 969-986.

Research output: Contribution to journalArticle

Sisson, TH, Ajayi, IO, Subbotina, N, Dodi, A, Rodansky, ES, Chibucos, LN, Kim, KK, Keshamouni, VG, White, ES, Zhou, Y, Higgins, PDR, Larsen, SD, Neubig, RR & Horowitz, JC 2015, 'Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis', American Journal of Pathology, vol. 185, no. 4, pp. 969-986. https://doi.org/10.1016/j.ajpath.2014.12.005
Sisson, Thomas H. ; Ajayi, Iyabode O. ; Subbotina, Natalya ; Dodi, Amos ; Rodansky, Eva S. ; Chibucos, Lauren N. ; Kim, Kevin K. ; Keshamouni, Venkateshwar G. ; White, Eric S. ; Zhou, Yong ; Higgins, Peter D R ; Larsen, Scott D. ; Neubig, Richard R. ; Horowitz, Jeffrey C. / Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis. In: American Journal of Pathology. 2015 ; Vol. 185, No. 4. pp. 969-986.
@article{2d8f09777b254991b01274ff279129c1,
title = "Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis",
abstract = "Myofibroblasts are crucial to the pathogenesis of tissue fibrosis. Their formation of stress fibers results in the release of myocardin-related transcription factor (MRTF), a transcriptional coactivator of serum response factor (SRF). MRTF-A (Mkl1)-deficient mice are protected from lung fibrosis. We hypothesized that the SRF/MRTF pathway inhibitor CCG-203971 would modulate myofibroblast function in vitro and limit lung fibrosis in vivo. Normal and idiopathic pulmonary fibrosis lung fibroblasts were treated with/without CCG-203971 (N-[4-chlorophenyl]-1-[3-(2-furanyl)benzoyl]-3-piperidine carboxamide) and/or Fas-activating antibody in the presence/absence of transforming growth factor (TGF)-β1, and apoptosis was assessed. In vivo studies examined the effect of therapeutically administered CCG-203971 on lung fibrosis in two distinct murine models of fibrosis induced by bleomycin or targeted type II alveolar epithelial injury. In vitro, CCG-203971 prevented nuclear localization of MRTF-A; increased the apoptotic susceptibility of normal and idiopathic pulmonary fibrosis fibroblasts; blocked TGF-β1-induced myofibroblast differentiation; and inhibited TGF-β1-induced expression of fibronectin, X-linked inhibitor of apoptosis, and plasminogen activator inhibitor-1. TGF-β1 did not protect fibroblasts or myofibroblasts from apoptosis in the presence of CCG-203971. In vivo, CCG-203971 significantly reduced lung collagen content in both murine models while decreasing alveolar plasminogen activator inhibitor-1 and promoting myofibroblast apoptosis. These data support a central role of the SRF/MRTF pathway in the pathobiology of lung fibrosis and suggest that its inhibition can help resolve lung fibrosis by promoting fibroblast apoptosis.",
author = "Sisson, {Thomas H.} and Ajayi, {Iyabode O.} and Natalya Subbotina and Amos Dodi and Rodansky, {Eva S.} and Chibucos, {Lauren N.} and Kim, {Kevin K.} and Keshamouni, {Venkateshwar G.} and White, {Eric S.} and Yong Zhou and Higgins, {Peter D R} and Larsen, {Scott D.} and Neubig, {Richard R.} and Horowitz, {Jeffrey C.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.ajpath.2014.12.005",
language = "English (US)",
volume = "185",
pages = "969--986",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis

AU - Sisson, Thomas H.

AU - Ajayi, Iyabode O.

AU - Subbotina, Natalya

AU - Dodi, Amos

AU - Rodansky, Eva S.

AU - Chibucos, Lauren N.

AU - Kim, Kevin K.

AU - Keshamouni, Venkateshwar G.

AU - White, Eric S.

AU - Zhou, Yong

AU - Higgins, Peter D R

AU - Larsen, Scott D.

AU - Neubig, Richard R.

AU - Horowitz, Jeffrey C.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Myofibroblasts are crucial to the pathogenesis of tissue fibrosis. Their formation of stress fibers results in the release of myocardin-related transcription factor (MRTF), a transcriptional coactivator of serum response factor (SRF). MRTF-A (Mkl1)-deficient mice are protected from lung fibrosis. We hypothesized that the SRF/MRTF pathway inhibitor CCG-203971 would modulate myofibroblast function in vitro and limit lung fibrosis in vivo. Normal and idiopathic pulmonary fibrosis lung fibroblasts were treated with/without CCG-203971 (N-[4-chlorophenyl]-1-[3-(2-furanyl)benzoyl]-3-piperidine carboxamide) and/or Fas-activating antibody in the presence/absence of transforming growth factor (TGF)-β1, and apoptosis was assessed. In vivo studies examined the effect of therapeutically administered CCG-203971 on lung fibrosis in two distinct murine models of fibrosis induced by bleomycin or targeted type II alveolar epithelial injury. In vitro, CCG-203971 prevented nuclear localization of MRTF-A; increased the apoptotic susceptibility of normal and idiopathic pulmonary fibrosis fibroblasts; blocked TGF-β1-induced myofibroblast differentiation; and inhibited TGF-β1-induced expression of fibronectin, X-linked inhibitor of apoptosis, and plasminogen activator inhibitor-1. TGF-β1 did not protect fibroblasts or myofibroblasts from apoptosis in the presence of CCG-203971. In vivo, CCG-203971 significantly reduced lung collagen content in both murine models while decreasing alveolar plasminogen activator inhibitor-1 and promoting myofibroblast apoptosis. These data support a central role of the SRF/MRTF pathway in the pathobiology of lung fibrosis and suggest that its inhibition can help resolve lung fibrosis by promoting fibroblast apoptosis.

AB - Myofibroblasts are crucial to the pathogenesis of tissue fibrosis. Their formation of stress fibers results in the release of myocardin-related transcription factor (MRTF), a transcriptional coactivator of serum response factor (SRF). MRTF-A (Mkl1)-deficient mice are protected from lung fibrosis. We hypothesized that the SRF/MRTF pathway inhibitor CCG-203971 would modulate myofibroblast function in vitro and limit lung fibrosis in vivo. Normal and idiopathic pulmonary fibrosis lung fibroblasts were treated with/without CCG-203971 (N-[4-chlorophenyl]-1-[3-(2-furanyl)benzoyl]-3-piperidine carboxamide) and/or Fas-activating antibody in the presence/absence of transforming growth factor (TGF)-β1, and apoptosis was assessed. In vivo studies examined the effect of therapeutically administered CCG-203971 on lung fibrosis in two distinct murine models of fibrosis induced by bleomycin or targeted type II alveolar epithelial injury. In vitro, CCG-203971 prevented nuclear localization of MRTF-A; increased the apoptotic susceptibility of normal and idiopathic pulmonary fibrosis fibroblasts; blocked TGF-β1-induced myofibroblast differentiation; and inhibited TGF-β1-induced expression of fibronectin, X-linked inhibitor of apoptosis, and plasminogen activator inhibitor-1. TGF-β1 did not protect fibroblasts or myofibroblasts from apoptosis in the presence of CCG-203971. In vivo, CCG-203971 significantly reduced lung collagen content in both murine models while decreasing alveolar plasminogen activator inhibitor-1 and promoting myofibroblast apoptosis. These data support a central role of the SRF/MRTF pathway in the pathobiology of lung fibrosis and suggest that its inhibition can help resolve lung fibrosis by promoting fibroblast apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=84925293244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925293244&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2014.12.005

DO - 10.1016/j.ajpath.2014.12.005

M3 - Article

C2 - 25681733

AN - SCOPUS:84925293244

VL - 185

SP - 969

EP - 986

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 4

ER -